Treatment of heart failure in patients with reduced left-
ventricular ejection fraction
Ugeskr Læger 2018;180:V06180453
Treatment of heart failure with reduced ejection fraction has undergone an enormous development over the latest three decades resulting in lower mortality. Standard treatment now includes use of angiotensin-converting-enzyme (ACE)-inhibitors, beta blockers and mineralocorticoid receptor antagonists. Diuretics are still the cornerstone in the symptomatic treatment of fluid retention. Combined angiotensin II receptor blockade and neprilysin inhibition is a new treatment option instead of ACE-inhibition for selected patients. Cardiac resynchronisation therapy and prophylactic implantable cardiac defibrillators further reduce mortality.